Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
September 20 2021 - 8:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced the
appointment of Jae Park, M.D., acting Chief of Cellular
Therapeutics at Memorial Sloan Kettering Cancer Center in New York,
to its Scientific Advisory Board (SAB). Dr. Park,
widely recognized as one of the world experts in cell therapies, is
the leading principal investigator of several clinical trials in
patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia
and acute lymphoblastic leukemia.
“We are honored to welcome Dr. Park to our Scientific Advisory
Board,” said Rafael Amado, M.D., Executive Vice President of
Research & Development and Chief Medical Officer of Allogene.
“Dr. Park’s groundbreaking research and experience treating
patients with CAR T and other novel immunotherapies will help us
maintain our leadership postion as we advance our platform for
patients with blood cancers and solid tumors.”
Dr. Park is Associate Attending Physician in the Division of
Hematologic Oncology, Leukemia Service, a Director of Adult Acute
Lymphoblastic Leukemia Program and the Acting Chief of Cellular
Therapeutics Service at Memorial Sloan Kettering Cancer Center in
New York, New York. Dr. Park received his medical degree from the
Johns Hopkins School of Medicine, and completed an internal
medicine residency at Massachusetts General Hospital and a
hematology/oncology fellowship at Memorial Sloan Kettering Cancer
Center. Dr. Park has written numerous peer-reviewed articles
appearing in New England Journal of Medicine, Science Translational
Medicine, Blood, Cancer Discovery and Journal of Clinical Oncology.
His research – which focuses on translating and establishing novel
targeted and immunotherapies for patients with hematologic
malignancies – has been recognized and funded by the The American
Society of Hematology, The American Association for Cancer
Research, The American Society of Clinical Oncology, The Leukemia
and Lymphoma Society, The Geoffrey Beene Research Foundation, and
The National Comprehensive Cancer Network.
The Allogene SAB comprises experts across oncology, immunology,
cell therapy, and drug discovery and development. Dr. Park joins
existing SAB members, Chair Ton Schumacher, Ph.D., Donald B.
Kohn, M.D., Malcom K. Brenner, M.D., Ph.D., Matthew Porteus,
M.D., Ph.D., Owen Witte, M.D., Stephan Grupp, M.D., Ph.D., Stephen
J. Forman, M.D., Thomas F. Gajewski, M.D., Ph.D., and Wendell Lim,
Ph.D.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) therapies for cancer. Led by a management team with
significant experience in cell therapy, Allogene is developing
a pipeline of “off-the-shelf” CAR T cell therapy candidates
with the goal of delivering readily available cell therapy
on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com,
and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for
Allogene This press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to develop allogeneic
CAR T therapies for cancer and the potential benefits of AlloCAR T
therapy. Various factors may cause differences between Allogene’s
expectations and actual results as discussed in greater detail in
Allogene’s filings with the SEC, including without limitation in
its Form 10-Q for the quarter ended June 30, 2021. Any
forward-looking statements that are made in this press release
speak only as of the date of this press release. Allogene assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
AlloCAR T is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2023 to Apr 2024